Chapter 5 The Endocannabinoid System as A Target for Novel Anxiolytic and Antidepressant Drugs

International Review of Neurobiology

Volumn 85, Issue , 2009, Pages 57-72

  Gaetani, Silvana ^a   Dipasquale, Pasqua ^a   Romano, Adele ^a   Righetti, Laura ^a   Cassano, Tommaso ^b   Piomelli, Daniele ^c   Cuomo, Vincenzo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ACYLGLYCEROL LIPASE; ANANDAMIDE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CANNABINOID 1 RECEPTOR; CANNABIS; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; FATTY ACID AMIDASE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; NEUROTRANSMITTER; RIMONABANT; AMIDASE; CANNABINOID; CANNABINOID RECEPTOR; FATTY-ACID AMIDE HYDROLASE;

ANXIETY DISORDER; BRAIN REGION; CANNABIS ADDICTION; CELL ACTIVATION; COMORBIDITY; DEPRESSION; DRUG POTENCY; DRUG RESEARCH; DRUG SELECTIVITY; DRUG TARGETING; EMOTIONAL DISORDER; EMOTIONALITY; ENZYME ACTIVITY; ENZYME INHIBITION; EUPHORIA; FATTY ACID METABOLISM; FATTY ACID TRANSPORT; HUMAN; IN VIVO STUDY; INHIBITION KINETICS; MOOD; MOOD DISORDER; NERVE CELL; NERVE CELL STIMULATION; NONHUMAN; OBESITY; OBSERVATIONAL STUDY; PANIC; PARANOIA; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR UPREGULATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYNAPSE VESICLE; TRANQUILIZING ACTIVITY; ANIMAL; ANIMAL BEHAVIOR; ANXIETY; ARTICLE; BRAIN; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG EFFECT; DRUG POTENTIATION; GENETICS; METABOLISM; MOUSE; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY;

AMIDOHYDROLASES; ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY; BEHAVIOR, ANIMAL; BRAIN; CANNABINOIDS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; ENDOCANNABINOIDS; HUMANS; MICE; MICE, KNOCKOUT; MOOD DISORDERS; RECEPTORS, CANNABINOID;

EID: 67650088165     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(09)85005-8     Document Type: Review

References (95)

1. Abel E.L. Changes in anxiety feelings following marihuana smoking. The alternation in feelings of anxiety resulting from the smoking of marihuana (Cannabis sativa L.). Br. J. Addict. Alcohol Other Drugs 66 (1997) 185-187
2. Ahn K., Johnson D.S., Fitzgerald L.R., Liimatta M., Arendse A., Stevenson T., Lund E.T., Nugent R.A., Nomanbhoy T.K., Alexander J.P., and Cravatt B.F. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry 46 (2007) 13019-13030
3. Azad S.C., Eder M., Marsicano G., Lutz B., Zieglgänsberger W., and Rammes G. Activation of the cannabinoid receptor type 1 decreases glutamatergic and gabaergic synaptic transmission in the lateral amygdala of the mouse. Learn. Mem. 10 (2003) 116-128
4. Beltramo M., Stella N., Calignano A., Lin S.Y., Makriyannis A., and Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277 (1997) 1094-1097
5. Berton O., and Nestler E.J. New approaches to antidepressant drug discovery: Beyond monoamines. Nat. Rev. Neurosci. 7 (2006) 137-151
6. Bisogno T., Howell F., Williams G., Minassi A., Cascio M.G., Ligresti A., Matias I., Schiano-Moriello A., Paul P., Williams E.J., Gangadharan U., Hobbs C., et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell Biol. 163 (2003) 463-468
7. Blankman J.L., Simon G.M., and Cravatt B.F. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 14 (2007) 1347-1356
8. Bortolato M., Campolongo P., Mangieri R.A., Scattoni M.L., Frau R., Trezza V., La Rana G., Russo R., Calignano A., Gessa G.L., Cuomo V., and Piomelli D. Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology 31 (2006) 2652-2659
9. Bortolato M., Mangieri R.A., Fu J., Kim J.H., Arguello O., Duranti A., Tontini A., Mor M., Tarzia G., and Piomelli D. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol. Psychiatry 62 (2007) 1103-1110
10. Budney A.J., Moore B.A., Vandrey R.G., and Hughes J.R. The time course and significance of cannabis withdrawal. J. Abnorm. Psychol. 112 (2003) 393-402
11. Budney A.J., Hughes J.R., Moore B.A., and Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am. J. Psychiatry 161 (2004) 1967-1977
12. Cahill L., and McGaugh J.L. Mechanisms of emotional arousal and lasting declarative memory. Trends Neurosci. 21 (1998) 294-299
13. Christensen R., Kristensen P.K., Bartels E.M., Bliddal H., and Astrup A. Efficacy and safety of the weight-loss drug rimonabant: A meta-analysis of randomised trials. Lancet 370 (2007) 1706-1713
14. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., and Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384 (1996) 83-87
15. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., and Lichtman A.H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. USA 98 (2001) 9371-9376
16. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
17. Di Marzo V. Targeting the endocannabinoid system: To enhance or reduce?. Nat. Rev. Drug Discov. 7 (2008) 438-455
18. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., and Pomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372 (1994) 686-691
19. Dinh T.P., Carpenter D., Leslie F.M., Freund T.F., Katona I., Sensi S.L., Kathuria S., and Piomelli D. Brain monoglyceride lipase participating in EC inactivation. Proc. Natl. Acad. Sci. USA 99 (2002) 10819-10824
20. Dinh T.P., Kathuria S., and Piomelli D. RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol. Pharmacol. 66 (2004) 1260-1264
21. Domschke K., Dannlowski U., Ohrmann P., Lawford B., Bauer J., Kugel H., Heindel W., Young R., Morris P., Arolt V., Deckert J., Suslow T., et al. Cannabinoid receptor 1 (CNR1) gene: Impact on antidepressant treatment response and emotion processing in major depression. Eur. Neuropsychopharmacol 18 (2008) 751-759
22. Fegley D., Kathuria S., Mercier R., Li C., Goutopoulos A., Makriyannis A., and Piomelli D. Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc. Natl. Acad. Sci. USA 101 (2004) 8756-8761
23. Freund T.F., Katona I., and Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 83 (2003) 1017-1066
24. Fu J., Gaetani S., Oveisi F., Lo Verme J., Serrano A., Rodríguez De Fonseca F., Rosengarth A., Luecke H., Di Giacomo B., Tarzia G., and Piomelli D. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425 (2003) 90-93
25. Gaetani S., Cuomo V., and Pomelli D. Anandamide hydrolysis: A new target for anti-anxiety drugs?. Trends Mol. Med. 9 (2003) 474-478
26. Gaetani S., Oveisi F., and Piomelli D. Modulation of meal pattern in the rat by the anorexic lipid mediator oleoylethanolamide. Neuropsychopharmacology 28 (2003) 1311-1316
27. Gaetani S., Kaye W.H., Cuomo V., and Piomelli D. Role of endocannabinoids and their analogues in obesity and eating disorders. Eat Weight Disord. 13 (2008) 42-48
28. Gaoni Y., and Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86 (1964) 1646-1647
29. Gerdeman G., and Lovinger D.M. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J. Neurophysiol 85 (2001) 468-471
30. Giuffrida A., Leweke F.M., Gerth C.W., Schreiber D., Koethe D., Faulhaber J., Klosterkötter J., and Piomelli D. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29 (2004) 2108-2114
31. Gobbi G., Bambico F.R., Mangieri R., Bortolato M., Campolongo P., Solinas M., Cassano T., Morgese M.G., Debonnel G., Duranti A., Tontini A., Tarzia G., et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc. Natl. Acad. Sci. USA 102 (2005) 18620-18625
32. Gregg J.M., Small E.W., Moore R., Raft D., and Toomey T.C. Emotional response to intravenous delta9tetrahydrocannabinol during oral surgery. J. Oral Surg. 34 (1976) 301-313
33. Hájos N., Ledent C., and Freund T.F. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106 (2001) 1-4
34. Hall W., and Solowij N. Adverse effects of cannabis. Lancet 352 (1998) 1611-1616
35. Haller J., Bakos N., Szirmay M., Ledent C., and Freund T.F. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur. J. Neurosci. 16 (2002) 1395-1398
36. Haller J., Varga B., Ledent C., Barna I., and Freund T.F. Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur. J. Neurosci. 19 (2004) 1906-1912
37. Haller J., Varga B., Ledent C., and Freund T.F. CB1 cannabinoid receptors mediate anxiolytic effects: Convergent genetic and pharmacological evidence with CB1-specific agents. Behav. Pharmacol. 15 (2004) 299-304
38. Hashimotodani Y., Ohno-Shosaku T., Maejima T., Fukami K., and Kano M. Pharmacological evidence for the involvement of diacylglycerol lipase in depolarization-induced endocanabinoid release. Neuropharmacology 54 (2008) 58-67
39. Hill M.N., Patel S., Carrier E.J., Rademacher D.J., Ormerod B.K., Hillard C.J., and Gorzalka B.B. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 30 (2005) 508-515
40. Hillard C.J., Wilkison D.M., Edgemond W.S., and Campbell W.B. Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain. Biochim. Biophys. Acta 1257 (1995) 249-256
41. Hillard C.J., Edgemond W.S., Jarrahian A., and Campbell W.B. Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J. Neurochem. 69 (1997) 631-638
42. Hohmann A.G., Suplita R.L., Bolton N.M., Neely M.H., Fegley D., Mangieri R., Krey J.F., Walker J.M., Holmes P.V., Crystal J.D., Duranti A., Tontini A., et al. An endocannabinoid mechanism for stress-induced analgesia. Nature 435 (2005) 1108-1112
43. Huang C.C., Lo S.W., and Hsu K.S. Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J. Physiol. 532 (2001) 731-748
44. 35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims. Mol. Psychiatry 9 (2004) 184-190
45. Jung K.M., Astarita G., Zhu C., Wallace M., Mackie K., and Piomelli D. A key role for diacylglycerol lipase-alpha in metabotropic glutamate receptor-dependent endocannabinoid mobilization. Mol. Pharmacol. 72 (2007) 612-621
46. Justinova Z., Manieri R.A., Bortolato M., Chefir S.I., Mukhin A.G., Clipper J.R., King A.R., Redhi G.H., Yasar S., Pomelli D., and Goldberg S.R. Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol. Psychiatry 64 (2008) 930-937
47. Kathuria S., Gaetani S., Fegley D., Valiño F., Duranti A., Tontini A., Mor M., Tarzia G., La Rana G., Malignano A., Giustino A., Tattoli M., et al. Modulation of anxiety through blockade of anandamide hydrolyis. Nat. Med. 9 (2003) 76-81
48. Katona I., Urbán G.M., Wallace M., Ledent C., Jung K.M., Piomelli D., Mackie K., and Freund T.F. Molecular composition of the endocannabinoid system at glutamatergic synapses. J. Neurosci. 26 (2006) 5628-5637
49. Leweke F.M., Giuffrida A., Koethe D., Schreiber D., Nolden B.M., Kranaster L., Neatby M.A., Schneider M., Gerth C.W., Hellmich M., Klosterkötter J., and Piomelli D. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: Impact of cannabis use. Schizophr. Res. 94 (2007) 29-36
50. Liu J., Wang L., Harvey-White J., Osei-Hyiaman D., Razdan R., Gong Q., Chan A.C., Zhou Z., Huang B.X., Kim H.Y., and Kunos G. A biosynthetic pathway for anandamide. Proc. Natl. Acad. Sci. USA 103 (2006) 13345-13350
51. Liu J., Wang L., Harvey-White J., Huang B.X., Kim H.Y., Luquet S., Palmiter R.D., Krystal G., Rai R., Mahadevan A., Razdan R.K., and Kunos G. Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology 54 (2008) 1-7
52. Llano I., Leresche N., and Marty A. Calcium entry increases the sensitivity of cerebellar Purkinje cells to applied GABA and decreases inhibitory synaptic currents. Neuron 6 (1991) 565-574
53. Long J.Z., Li W., Booker L., Burston J.J., Kinsey S.G., Schlosburg J.E., Pavón F.J., Serrano A.M., Selley D.E., Parsons L.H., Lichtman A.H., and Cravatt B.F. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat. Chem. Biol. 5 (2008) 37-44
54. LoVerme J., Fu J., Astarita G., La Rana G., Russo R., Calignano A., and Piomelli D. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharmacol. 67 (2005) 15-29
55. LoVerme J., Russo R., La Rana G., Fu J., Farthing J., Mattace-Raso G., Meli R., Hohmann A., Calignano A., and Piomelli D. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J. Pharmacol. Exp. Ther. 319 (2006) 1051-1061
56. Marsicano G., Wotjak C.T., Azad S.C., Bisogno T., Rammes G., Cascio M.G., Hermann H., Tang J., Hofmann C., Zieglgänsberger W., Di Marzo V., and Lutz B. The endogenous cannabinoid system controls extinction of aversive memories. Nature 418 (2002) 530-534
57. Martin M., Ledent C., Parmentier M., Maldonado R., and Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology 159 (2002) 379-387
58. McDonald A.J., and Mascagni F. Localization of the CB1 type cannabinoid receptor in the rat basolateral amygdala: High concentrations in a subpopulation of cholecystokinin-containing interneurons. Neuroscience 107 (2001) 641-652
59. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., Compton D.R., Pertwee R.G., Griffin G., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50 (1995) 83-90
60. Millan M.J. The neurobiology and control of anxious states. Prog. Neurobiol. 70 (2003) 83-244
61. Mor M., Rivara S., Lodola A., Plazzi P.V., Tarzia G., Duranti A., Tontini A., Piersanti G., Kathuria S., and Piomelli D. Cyclohexylcarbamic acid 3′- or 4′-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: Synthesis, quantitative structure-activity relationships, and molecular modeling studies. J. Med. Chem. 47 (2004) 4998-5008
62. Moreira F.A., Kaiser N., Monory K., and Lutz B. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology 54 (2008) 141-150
63. Muccioli G.G., Xu C., Odah E., Cudaback E., Cisneros J.A., Lambert D.M., López Rodríguez M.L., Bajjalieh S., and Stella N. Identification of a novel endocannabinoid-hydrolyzing enzyme expressed by microglial cells. J. Neurosci. 27 (2007) 2883-2889
64. Naidu P.S., Varvel S.A., Ahn K., Cravatt B.F., Martin B.R., and Lichtman A.H. Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology 192 (2007) 61-70
65. Naliboff B.D., Rickles W.H., Cohen M.J., and Naimark R.S. Interactions of marijuana and induced stress: Forearm blood flow, heart rate, and skin conductance. Psychophysiology 13 (1976) 517-522
66. Navarro M., Hernández E., Muñoz R.M., del Arco I., Villanúa M.A., Carrera M.R., and Rodríguez de Fonseca F. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responsesin the rat. Neuroreport 8 (1997) 491-496
67. Okamoto Y., Morishita J., Wang J., Schmid P.C., Krebsbach R.J., Schmid H.H., and Ueda N. Mammalian cells stably overexpressing N-acylphosphatidylethanolamine-hydrolysing phospholipase D exhibit significantly decreased levels of N-acylphosphatidylethanolamines. Biochem. J. 389 (2005) 241-247
68. Onaivi E.S., Chakrabarti A., Gwebu E.T., and Chaudhuri G. Neurobehavioral effects of D9-THC and cannabinoid (CB1) receptor gene expression in mice. Behav. Brain Res. 72 (1995) 115-125
69. Patel S., and Hillard C.J. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: Further evidence for an anxiolytic role for endogenous cannabinoid signaling. J. Pharmacol. Exp. Ther. 318 (2006) 304-311
70. Patel S., Roelke C.T., Rademacher D.J., Cullinan W.E., and Hillard C.J. Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 145 (2004) 5431-5438
71. Piomelli D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. 4 (2003) 873-884
72. Piomelli D., Beltramo M., Glasnapp S., Lin S.Y., Goutopoulos A., Xie X.Q., and Makriyannis A. Structural determinants for recognition and translocation by the anandamide transporter. Proc. Natl. Acad. Sci. USA 96 (1999) 5802-5807
73. Piomelli D., Tarzia G., Duranti A., Tontini A., Mor M., Compton T.R., Dasse O., Monaghan E.P., Parrott J.A., and Putman D. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev. 12 (2006) 21-38
74. Pitler T.A., and Alger B.E. Postsynaptic spike firing reduces synaptic GABAA responses in hippocampal pyramidal cells. J. Neurosci. 12 (1992) 4122-4132
75. Rademacher D.J., and Hillard C.J. Interactions between endocannabinoids and stress-induced decreased sensitivity to natural reward. Prog. Neuropsychopharmacol. Biol. Psychiatry 31 (2007) 633-641
76. Robbe D., Alonso G., Duchamp F., Bockaert J., and Manzoni O.J. Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. J. Neurosci. 21 (2001) 109-116
77. Rodríguez de Fonseca F., Carrera M.R., Navarro M., Koob G.F., and Weiss F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 276 (1997) 2050-2054
78. Rodríguez de Fonseca F., Navarro M., Gómez R., Escuredo L., Nava F., Fu J., Murillo-Rodríguez E., Giuffrida A., LoVerme J., Gaetani S., Kathuria S., Gall C., et al. An anorexic lipid mediator regulated by feeding. Nature 414 (2001) 209-212
79. Schmid P.C., Zuzarte-Augustin M.L., and Schmid H.H. Properties of rat liver N-acylethanolamin amidohydrolase. J. Biol. Chem. 260 (1985) 14145-14149
80. Schwartz G.J., Fu J., Astarita G., Li X., Gaetani S., Campolongo P., Cuomo V., and Piomelli D. The lipid messenger OEA links dietary fat intake to satiety. Cell Metab. 8 (2008) 281-288
81. Simon G.M., and Cravatt B.F. Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway. J. Biol. Chem. 281 (2006) 26465-26472
82. Stella N., and Piomelli D. Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur. J. Pharmacol. 425 (2001) 189-196
83. Stella N., Schweitzer P., and Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 388 (1997) 773-778
84. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., and Waku K. 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215 (1995) 89-97
85. Tarzia G., Duranti A., Tontini A., Piersanti G., Mor M., Rivara S., Plazzi P.V., Park C., Kathuria S., and Piomelli D. Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acidamide hydrolase inhibitors. J. Med. Chem. 46 (2003) 2352-2360
86. Tournier M., Sorbara F., Gindre C., Swendsen J.D., and Verdoux H. Cannabis use and anxiety in daily life: A naturalistic investigation in a non-clinical population. Psychiatry Res. 118 (2003) 1-8
87. Tsuboi K., Takezaki N., and Ueda N. The N-acylethanolamine-hydrolyzing acid amidase (NAAA). Chem. Biodivers. 4 (2007) 1914-1925
88. Urigüen L., Pérez-Rial S., Ledent C., Palomo T., and Manzanares J. Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology 46 (2004) 966-973
89. Vandrey R.G., Budney A.J., Moore B.A., and Hughes J.R. A cross-study comparison of cannabis and tobacco withdrawal. Am. J. Addict. 14 (2005) 54-63
90. Vandrey R.G., Budney A.J., Hughes J.R., and Liguori A. A within-subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substances. Drug Alcohol Depend. 92 (2008) 48-54
91. Varvel S.A., Wise L.E., Niyuhire F., Cravatt B.F., and Lichtman A.H. Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task. Neuropsychopharmacology 32 (2007) 1032-1041
92. Viveros M.P., Marco E.M., and File S.E. Endocannabinoid system and stress and anxiety responses. Pharmacol. Biochem. Behav. 81 (2005) 331-342
93. Wachtel S.R., ElSohly M.A., Ross S.A., Ambre J., and de Wit H. Comparison of the subjective effects of D(9)-tetrahydrocannabinol and marijuana in humans. Psychopharmacology (Berl.) 161 (2002) 331-339
94. Wei B.Q., Mikkelsen T.S., McKinney M.K., Lander E.S., and Cravatt B.F. A second fatty acid amide hydrolase with variable distribution among placental mammals. J. Biol. Chem. 281 (2006) 36569-36578
95. Zuardi A.W., Shirakawa I., Finkelfarb E., and Karniol I.G. Action of cannabidiol on the anxiety and other effects produced by D9-THC in normal subjects. Psychopharmacology (Berl.) 76 (1982) 245-250